402856-42-2

Tesofensine, is a serotonin–noradrenaline–dopamine reuptake inhibitor from the phenyltropane family of drugs, which is currently in clinical development for the treatment of obesity.

One of the most significant benefits of Tesofensine is that it can help patients achieve long-term weight loss goals. Unlike other medications, this drug has been shown to produce results when taken within 6 months. Another benefit of Tesofensine is its ability to improve metabolic function in overweight individuals. This medication helps regulate blood sugar levels and reduce insulin resistance by suppressing appetite and reducing fat absorption. When the body is insulin resistant, it creates a condition called diabetes.

Common side effects include dry mouth, headache, nausea, insomnia, diarrhea, and constipation. Blood pressure and heart rate were increased by 1–3 mmHg and up to 8 bpm, respectively.

The main synthetic method of Tesofensine is as follows: first methyl esterify with tropinone, then reduce to alcohol intermediate by reducing agent, then make alkene intermediate by dehydrating agent, then alkene make intermediate ester compound by f